$GUTS News

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Fractyl Health Inc (NASDAQ:GUTS) Q1 Earnings: Net Income Swing Masks Core Operating Burn as Key Revita Data Readout Looms

Fractyl Health Q1 2026 Earnings Call: Complete Transcript

Fractyl Health Q1 EPS $0.06 Beats $(0.16) Estimate

Fractyl Health Receives Clinical Trial Application Authorization In Netherlands To Initiate Phase 1/2 First-in-human Study Of RJVA-001, Expects To Start Dosing And Report Preliminary Data In 2H of 2026

HC Wainwright & Co. Reiterates Buy on Fractyl Health, Maintains $8 Price Target

Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know

Fractyl Health (NASDAQ:GUTS) Posts Narrower-Than-Expected Loss Ahead of Pivotal Trial Readout

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Fractyl Health Q4 EPS $(0.07) Beats $(0.19) Estimate

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

Fractyl Health Completes Participant Randomization In REMAIN-1 Pivotal Cohort Evaluating Revita For Weight Maintenance Following GLP-1 Therapy Discontinuation

Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts

Fractyl Health shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight and lowered its price target from $8 to $2.

Fractyl Health shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight and lowered its price target from $8 to $2.

Morgan Stanley Downgrades Fractyl Health to Equal-Weight, Lowers Price Target to $2